ASCVD Risk Estimator Plus
The updated ASCVD Risk Estimator Plus uses recent science and user feedback to help a clinician and patient build a customized risk lowering plan by estimating and monitoring change in 10 year ASCVD risk.
Use the app to:
The AnticoagEvaluator helps clinicians make well-informed decisions on antithrombotic therapy for their non-valvular AF patients. Use this app to:
New! The BridgeAnticoag app supports clinicians across specialties in safely managing anticoagulation around an invasive procedure for NVAF patients. The app calculates patient and procedural risk to provide individualized advice that balances bleed and stroke risk.
Use the app to assess whether and how to:
Email yourself a detailed report of the app assessment.
The ACC's CardioSmart Heart Explorer App has been revamped to further the clinician/patient relationship at the point of care. The newly enhanced, high-resolution cardiac graphics and animations are designed to help effectively review and discuss common heart problems and treatment options with patients. New to the app, heart failure and atrial fibrillation information can be emailed directly to patients through the app.
The ACC DAPT Risk Calculator App provides decision support for clinicians evaluating the continuation of DAPT therapy for patients at least 12 months post-PCI procedure, and the risk/benefit of continuing or discontinuing DAPT. The App provides a DAPT Risk Score as a numerical value between -2 and +9, where higher DAPT scores suggest that the benefit/risk ratio with prolonged DAPT may be favorable. Conversely, lower DAPT scores suggest that the benefit/risk ratio with prolonged DAPT is NOT favorable. It also calculates the percentage of risk for three end points: myocardial infarction (MI), stent thrombosis, major adverse cardiovascular and cerebrovascular events (MACCE), and bleeding.
The ACC's Guideline Clinical App is the mobile home of clinical guideline content and tools for clinicians caring for patients with cardiovascular disease. You can access guideline recommendations, "10 Points" summaries, and tools such as risk scores, calculators and algorithms. Customize your App by using the bookmark, note-taking, and shareable PDF features.
The STS/ACC TAVR In-Hospital Mortality Risk App assists clinicians in determining the predicted in-hospital mortality risk of a patient who is considering TAVR as a treatment option for AVR. Clinicians can evaluate a patient’s mortality risk and compare it to the national average based on STS/ACC TVT Registry data.